Latest news

Debiopharm Statement regarding its Strategic Committee Members

Debiopharm interviewed by Biotech Finances to talk about our evergreen fund

Voluntis on receiving FDA 510(K) Clearance and expanding

Voluntis on receiving the CE Mark for Oleena

Voluntis expanding their global pharma collaborations

Novadiscovery announces new clinical simulation collaboration with Takeda

Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant

Nucleai Partners With Sheba Medical Center’s ARC Innovation Center For a New Strategic Data Collaboration

BC Platforms and Genomenon combine forces to improve clinical genomics diagnosis and research